Note: Descriptions are shown in the official language in which they were submitted.
X-10198
CA 02214872 1997-09-08
-1-
BENZOTHIOPHENE COMPOUNDS, COMPOSITIONS,
AND METHODS
Osteoporosis describes a group of diseases which arises
from diverse etiologies, but which are characterized by the
net loss of bone mass per unit volume. The consequence of
this loss of bone mass and resulting bone fracture is the
failure of the skeleton to provide adequate support for the
body. One of the most common types of osteoporosis is
associated with menopause. Most women lose from about 20%
to about 60% of the bone mass in the trabecular compartment
of the bone within 3 to 6 years after the cessation of
menses. This rapid loss is generally associated with an
increase of bone resorption and formation. However, the
resorptive cycle is more dominant and the result is a net
loss of bone mass. Osteoporosis is a common and serious
disease among postmenopausal women.
There are an estimated 25 million women in the United
States alone who are afflicted with this disease. The
results of osteoporosis are personally harmful, and also
account for a large economic loss due to its chronicity and
the need for extensive and long term support
(hospitalization and nursing home care) from the disease
sequelae. This is especially true in more elderly patients.
Additionally, although osteoporosis is generally not thought
of as a life threatening condition, a 20% to 30% mortality
rate is related to hip fractures in elderly women. A large
percentage of this mortality rate can be directly associated
with postmenopausal osteoporosis.
The most vulnerable tissue in the bone to the effects
of postmenopausal osteoporosis is the trabecular bone. This
tissue is often referred to as spongy or cancellous bone and
is particularly concentrated near the ends of the bone (near
the joints) and in the vertebrae of the spine. The
trabecular tissue is characterized by small osteoid
structures which interconnect with each other, as well as
the more solid and dense cortical tissue which makes up the
X-10198
CA 02214872 1997-09-08
-2-
outer surface and central shaft of the bone. This
interconnected network of trabeculae gives lateral support
to the outer cortical structure and is critical to the
biomechanical strength of the overall structure. In
postmenopausal osteoporosis, it is primarily the net
resorption and loss of the trabeculae which leads to the
failure and fracture of bone. In light of the loss of the
trabeculae in the postmenopausal woman, it is not surprising
that the most common fractures are those associated with
bones which are highly dependent on trabecular support, for
example, the vertebrae, the neck of the weight-bearing bones
such as the femur and the forearm. Indeed, hip fracture,
collies fractures, and vertebral crush fractures are
hallmarks of postmenopausal osteoporosis.
The most generally accepted method for the treatment
of postmenopausal osteoporosis is estrogen replacement
therapy. Although therapy is generally successful, patient
compliance with the therapy is low, primarily because
estrogen treatment frequently produces undesirable side
effects. An additional method of treatment would be the
administration of a bisphosphonate compound, such as, for
example, Fosamax° (Merck & Co., Inc.).
Throughout premenopausal time, most women have less
incidence of cardiovascular disease than men of the same
age. Following menopause, however, the rate of
cardiovascular disease in women slowly increases to match
the rate seen in men. This loss of protection has been
linked to the loss of estrogen and, in particular, to the
loss of estrogen's ability to regulate the levels of serum
lipids. The nature of estrogen's ability to regulate serum
lipids is not well understood, but evidence to date
indicates that estrogen can up regulate the low density
lipid (LDL) receptors in the liver to remove excess
cholesterol. Additionally, estrogen appears to have some
effect on the biosynthesis of cholesterol, and other
beneficial effects on cardiovascular health.
CA 02214872 1998-09-04
X-10198
-3-
It has been reported in the literature that serum lipid
levels in postmenopausal women having estrogen replacement
therapy return to concentrations found in the premenopausal
state. Thus, estrogen would appear to be a reasonable
treatment for this condition. However, the side effects of
estrogen replacement therapy are not acceptable to many
women, thus limiting the use of this therapy. An ideal
therapy for this condition would be an agent which regulates
serum lipid levels in a manner analogous to estrogen, but
which is devoid of the side effects and ris~:s associated
with estrogen therapy.
Estrogen dependent cancers are major diseases effecting
both women, and to a lesser extent, men. Cancer cells of
this type are dependent on a source of estrogen to maintain
the original tumor as well as to proliferate and metastasize
to other locations. The most common forms of estrogen
dependent cancer are breast and uterine carcinomas. Current
chemotherapy of these diseases relies primarily on the use
of anti-estrogens, predominately tamoxifen. The use of
tamoxifen, although efficaceous, is not without undesirable
side-effects, for example, estrogen agonist properties, such
as uterine hypertrophy and carcinogenic potential.
Compounds of the current invention, while showing the same or
better potential for anti-cancer activity, also demonstrate
a lower potential for estrogen agonist activity.
In response to the clear need for new pharmaceutical
agents which are capable of alleviating the symptoms
described herein, the instant invention provides
benzo[b]thiophene compounds, pharmaceutical formulations,
and methods of using said compounds for the inhibition of
the disease states as indicated herein.
X-10198
CA 02214872 1997-09-08
-4-
formula I:
The instant invention relates to compounds of
R2
R1
I
wherein:
R1 is -H, -OH, -O(C1-C4 alkyl),
-OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), -OCOAr, -O(CO)OAr,
where Ar is phenyl or optionally substituted phenyl, or -
OS02(C2-C6 alkyl);
R2 is -H, -OH, -O(C1-C4 alkyl),
-OCO(C1-C6 alkyl), -O(CO)0(C1-C6 alkyl), -OCOAr, -O(CO)OAr,
where Ar is phenyl or optionally substituted phenyl, -
OS02(C2-C6 alkyl), -C1, or -F;
R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-
pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino,
dimethylamino, diethylamino, or 1-hexamethyleneimino; and
n is 2, 3, or 4;
or a pharmaceutically acceptable salt or solvate thereof.
The instant invention further provides pharmaceutical
formulations containing compounds of formula I, and the use
of said compounds at least for the inhibition of bone loss
or bone resorption, particularly osteoporosis, and
cardiovascular-related pathological conditions, including
hyperlipidemia, and estrogen-dependent cancer.
CA 02214872 1998-09-04
X-10198
General terms used in the description c~f compounds
herein described bear their usual meaning . For example,
"C1-C6 alkyl" refers to straight or branched aliphatic
chains of 1 to E~ carbon atoms including methyl, ethyl,
propyl, isopropyl, butyl, n-butyl, pentyl, -wsopentyl, hexyl,
isohexyl, and the like. Similarly, the term "-OC1-C4 alkyl"
represents a C--C4 alkyl group attached through an oxygen
such as, for example, methoxy, ethoxy, n-propoxy,
isopropoxy, and r_he like. Of these Cl-C4 alkoxy groups,
methoxy is highly preferred.
The term ""substituted phenyl." refers to a phenyl group
having one or more substituents selected from the group
consisting of C1-C4 alkyl, -OC1-C4 alkyl, hydroxy, vitro,
chloro, fluoro, or tri(chloro or fluoro;metl-~.=,rl.
The term "hydroxy protecting group" cor:templates
numerous functionalities used in the literature to protect a
hydroxyl function during a chemical sequence and which can
be removed to yield the phenol. Included within this group
are acyls, mesylates, tosylates, benzyl, alkylsilyloxys, C1-
C4 alkyls, and~the like. Numerous reactions for the
formation and removal of such protecting groups are
described in a number of standard works including, for
example, J.G.W. McOmie, Protective Groups in Organic
Chemistry, Plenum Press (London and New York, 1973); Green,
T.W., Protective Groups in Organic Synthesis, Wiley, (New
York, 1981) ; and The Peptides, Vol. I, Schroder and Liibke,
Academic Press (London and New York, 1965). Methods for
removing preferred hydroxy protecting groups, particularly
methyl, are essentially as described in, the ~,xamples, infra.
The term "leaving group" means a chemical entity which
is capable of being displaced by an amino function via an
SN2 reaction. Such reactions are well known in the art and
such groups would include halogens, mesylates, tosylates,
and the like. A preferred leaving group is bromo.
The term "inhibit" includes its general_Ly accepted
meaning which includes prohibiting, preventlTlg, restraining,
X-10198
CA 02214872 1997-09-08
-6-
and slowing, stopping, or reversing progression, severity,
or ameliorating a resultant symptom or effect.
The term "solvate" represents an aggregate that
comprises one or more molecules of the solute, such as a
formula I compound, with one or more molecules of solvent.
The compounds of formula I are derivatives of
benzo[b]thiophene which is named and numbered according to
the Ring Index, The American Chemical Society, as follows:
4
5 n ,.
2
6
7
Compounds of formula I include, but are not limited to:
2-(4-Methoxyphenyl)-3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-6-
methoxybenzo[b]thiophene hydrochloride;
2-(4-Methoxyphenyl)-3-[3-[3-(1-piperidinyl)propoxy]phenyl]-
6-methoxybenzo-[b]thiophene hydrochloride;
2-(4-Methoxyphenyl)-3-[3-[4-(1-piperidinyl)butoxy]phenyl]-6-
methoxybenzo[b]thiophene hydrochloride;
2-(4-Hydroxyphenyl)-3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-6-
hydroxybenzo[b]thiophene hydrochloride;
2-(4-Hydroxyphenyl)-3-[3-(1-piperidinyl)propoxy]phenyl]-6-
hydroxybenzo[b]thiophene;
2-(4-Hydroxyphenyl)-3-[3-(1-piperidinyl)butoxy]phenyl]-6-
hydroxybenzo[b]thiophene hydrochloride;
2-(4-Methoxyphenyl)-3-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
6-methoxybenzo[b]thiophene hydrochloride;
2-(4-Methoxyphenyl)-3-[3-[3-(1-pyrrolidinyl)propoxy]phenyl]-
6-methoxybenzo[b]thiophene hydrochloride;
2-(4-Methoxyphenyl)-3-[3-[4-(1-pyrrolidinyl)butoxy]phenyl]-
6-methoxybenzo[b]thiophene hydrochloride;
X-10198
CA 02214872 1997-09-08
-
2-(4-Hydroxyphenyl)-3-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-
6-hydroxybenzo[b]thiophene hydrochloride;
2-(4-Hydroxyphenyl)-3-[3-(1-pyrrolidinyl)propoxy]phenyl]-6-
hydroxybenzo[b]thiophene;
2-(4-Hydroxyphenyl)-3-[3-(1-pyrrolidinyl)butoxy]phenyl]-6-
hydroxybenzo[b]thiophene hydrochloride;
and the like.
Preferred embodiments of the current invention are
those compounds wherein n is three and R3 is piperidinyl.
Several synthetic pathways are available for preparing
the compounds of the instant invention. One synthetic route
is illustrated'in Scheme I, below.
X-10198
CA 02214872 1997-09-08
_g_
Scheme I
v
OH ~ 1. n-BuLi
C 1 2. B(OiPr)3
Br Kz CD3 . DMF Br 3 . HC 1 B ( OH ) z
IV V
Br
-R Br2 /CC14 ~ ~/~-R2
Rl S 2 CHC13 R1 S
III
I I Pd ( PPh3 ) q
Na2 C03
EtOH
Toluene
-OH '' j-0
Pd(0) Blac ~k
S ~~ R2 NH4COOH S ~-R2
R1 R1
VII VI
C1 (CH2) nR3 XII
K2C03 ,
DMF, HC1
~O(CH2)nR3
~- O ( CH2 ) nR3 BBr3
CHZCl2,
R2 HC1 OH
R S HO S
1
I . Ia
CA 02214872 1998-09-04
X-10198
_q_
In the processes for preparing compounds of the present
invention, the starting material for the benzo[b]thiophene
derivatives are benzo[b]thiophene precursors of formula II:
x~
II
wherein R1 and;,R2 have their previous meanings.
A compound of formula II may be prepared in accordance
with the methods in Jones et al., U.S. Pat. No. 4,133,814,
issued January 9, 1979.
A compound of formula II is brominated with one
equivalent of bromine in a suitable chlorinated solvent,
such as chloroform, carbon tetrachloride, or mixtures
thereof. The substrate is heated in the solvent to reflux.
The bromine is added dropwise as the reaction mixture is slowly
cooled to room temperature to give a compound of formula
III, which is brominated at the 3-position:
Br
R
R~/ ~% _ S
III
wherein R1 and R2 have their previous meanings.
Benzyl chloride and m-bromophenol are coupled in DMF
with excess potassium carbonate overnight at room
temperature to give a benzyl-protected phenolic compound of
formula IV.
X-10198
CA 02214872 1997-09-08
-10-
O
Br IV
The benzyl protecting group is one of many groups which
may be used to protect the phenol during the subsequent
coupling reaction. See, for example, J.W. Barton,
"Protective Groups in Organic Chemistry;, J.G. W. McOmie
(ed.), Plenum Press, New York, NY, 1973, Chapter 2, and T.
W. Green, "Protective Groups in Organic Synthesis", John
Wiley and Sons, New York, NY, 1981, Chapter 7.
The 3-benzyloxybromobenzene of formula IV is converted
to the boronic acid derivative by dissolving in THF and
adding one equivalent of n-butyllithium at -78°C. After
stirring at -78°C for approximately 30 minutes, one
equivalent of triisopropyl borate is added and the reaction
is slowly warmed to room temperature, followed by
acidification with aqueous hydrochloric acid to give a 3-
benzyloxybenzene boronic acid compound of formula V.
O
B (OH) z V
A compound of formula III and a compound of formula V
are then combined in 10% ethanol in toluene with aqueous
sodium carbonate and catalytic
tetrakis(triphenylphosphine)palladium (0) and heated to
reflux for 2-3. hours. Conventional thin layer
chromatography is typically used to monitor the completion
of the reaction, which yields a compound of formula VI.
X-10198
CA 02214872 1997-09-08
-11-
/ \
-, \ /
R2
R1/ ~% ~S
VI
wherein R1 and R2 have their previous meanings.
The benzyloxy protecting group on a compound of formula
VI may be removed by any of the available standard methods,
such as hydrogenation, using catalytic palladium on
activated carbon in THF, under pressure. Alternatively, the
deprotection may be performed by refluxing for 30 minutes in
an ethyl acetate/ethanol/water solvent system with one
equivalent of palladium (0) black and five equivalents of
ammonium formate giving the phenolic compound of formula
VII. (See, for example, J.W. Barton, ibid.)
R2
RZ
VII
wherein R1 and. R2 are as previously defined.
The phenolic compounds of formula VII derived above may
be alkylated by adding a compound of formula XII in DMF at
room temperature, usually overnight with an excess of dry
potassium carbonate:
X-10198
CA 02214872 1997-09-08
-12-
- C1-(CH2)n-R3
XII
wherein R3 and n have their previous meanings.
Alternately, the above phenol may be alkylated with an
excess of a di-haloalkyl moiety to yield an oxy-alkyl-halo
derivative, for example, a compound of formula XIII.
Preferred halogens would be chloro or bromo, with bromo
being particularly preferred.
)n Br (C1)
R2
R1
XIII
wherein R1, R2, and n are as previously defined.
A compound of formula XIII may be converted to a
compound of formula I by displacing the halogen with an
appropriate amine in the presence of an inorganic base such
as K2C03 or the like. Compounds of formula I wherein R1 and
R2 are esters or sulfonates may be derived from de-
methylating the mono- or di-methoxy compounds with A1C13,
BC13, and the like, and acylating with the appropriate acyl
or sulfonyl moiety. The methoxy groups are removed using an
appropriate protocol, such that cleavage of the oxy-alkyl-
base side-chain does not occur. This may be accomplished by
converting the~basic nitrogen to its hydrochloride salt.
X-10198
CA 02214872 1997-09-08
-13-
~R3
R2
RZ
I
wherein R1, R2: R3, and n are as previously defined.
In the case where n is 4 in a compound of formula Ib,
an alternate synthetic approach is taken, as 1-(4-
chlorobutyl)piperidine hydrochloride is not readily
available. A compound of formula VII is alkylated with 1,4-
dibromobutane with excess dry potassium carbonate in 2-
butonone at reflux for one hour, resulting in a compound of
formula IX.
~Br
Rz
R1
IX
wherein R1 and R2 are as previously defined.
A compound of formula IX is then reacted with the
appropriate base, such as for example piperidine, and excess
dry potassium carbonate in DMF at reflux for 3 hours giving
a compound of formula Ib. The HCl salt is made using
standard techniques.
X-10198
CA 02214872 1997-09-08
-14-
HC1 O (CH2) 4R3
R2
R1
Ib
wherein R1, R2, and R3 are as previously defined.
A compound of formula I wherein R1 and R2 are both -
OCH3 may be demethylated by reacting with 2.5 equivalents of
boron tribromide in dichloromethane at 0°C for 3 hours to
provide compounds of formula Ia. The HC1 salt is made by
standard techniques.
~R3
OH
Ia
Compounds of formula Ia and Ib are encompassed by and
included in the definition of a compound of formula I.
Although the free-base form of formula I compounds can
be used in the methods of the instant invention, it is
preferred to prepare and use a pharmaceutically acceptable
salt form. The term "pharmaceutically acceptable salt"
refers to either acid or base addition salts which are known
to be non-toxic and are commonly used in the pharmaceutical
literature. The pharmaceutically acceptable salts generally
X-10198
CA 02214872 1997-09-08
-15-
have enhanced solubility characteristics compared to the
compound from which they are derived, and thus are often
more amenable to formulation as liquids or emulsions. The
compounds used in the methods of this invention primarily
form pharmaceutically acceptable acid addition salts with a
wide variety of organic and inorganic acids, and include the
physiologically acceptable salts which are often used in
pharmaceutical~chemistry. Such salts are also part of this
invention.
Typical inorganic acids used to form such salts include
hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric,
phosphoric, hypophosphoric, and the like. Salts derived
from organic acids, such as aliphatic mono and dicarboxylic
acids, phenyl-substituted alkanoic acids, hydroxyalkanoic
and hydroxyalkandioic acids, aromatic acids, aliphatic and
aromatic sulfonic acids, may also be used. Such
pharmaceutically acceptable salts thus include acetate,
phenylacetate, trifluoroacetate, acrylate, ascorbate,
benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate,
methoxybenzoate, methylbenzoate, o-acetoxybenzoate,
naphthalene-2-benzoate, bromide, isobutyrate,
phenylbutyrate, ~-hydroxybutyrate, butyne-1,4-dioate,
hexyne-1,4-dioate, caproate, caprylate, chloride, cinnamate,
citrate, formate, fumarate, glycolate, heptanoate,
hippurate, lactate, malate, maleate, hydroxymaleate,
malonate, mandelate, mesylate, nicotinate, isonicotinate,
nitrate, oxalate, phthalate, terephthalate, phosphate,
monohydrogenphosphate, dihydrogenphosphate, metaphosphate,
pyrrophosphate, propiolate, propionate, phenylpropionate,
salicylate, sebacate, succinate, suberate, sulfate,
bisulfate, pyrosulfate, sulfite, bisulfate, sulfonate,
benzenesulfonate, p-bromophenylsulfonate,
chlorobenzenesulfonate, ethanesulfonate, 2-
hydroxyethanesulfonate, methanesulfonate, naphthalene-1-
sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate,
xylenesulfonate, tartarate, and the like. A preferred salt
is the hydrochloride salt.
X-10198
CA 02214872 1997-09-08
-16-
The pharmaceutically acceptable acid addition salts are
typically formed by reacting a compound of formula I with an
equimolar or excess amount of acid. The reactants are
generally combined in a mutual solvent such as diethyl ether
or ethyl acetate. The salt normally precipitates out of
solution within about one hour to 10 days and can be
isolated by filtration, or the solvent can be stripped off
by conventional means. The instant invention further
provides for pharmaceutically acceptable formulations for
administering to a mammal, including humans, in need of
treatment, which comprises an effective amount of a compound
of formula I and a pharmaceutically acceptable diluent or
carrier.
As used herein, the term "effective amount" means an
amount of compound of the instant invention which is capable
of inhibiting, alleviating, ameliorating, treating, or
preventing further symptoms in mammals, including humans,
suffering from bone loss or bone resorption, particularly
osteoporosis, and cardiovascular-related pathological
conditions, including hyperlipidemia.
In the case of estrogen-dependent cancers, the term
"effective amount" means the amount of compound of the
instant invention which is capable of alleviating,
ameliorating, inhibiting cancer growth, treating, or
preventing the cancer and/or its symptoms in mammals,
including humans.
By "pharmaceutically acceptable formulation" it is
meant that the carrier, diluent, excipients and salt must be
compatible with the active ingredient (a compound of formula
I) of the formulation, and not be deleterious to the
recipient thereof. Pharmaceutical formulations can be
prepared by procedures known in the art. For example, the
compounds of this invention can be formulated with common
excipients, diluents, or carriers, and formed into tablets,
capsules, and the like. Examples of excipients, diluents,
and carriers that are suitable for such formulations include
the following: fillers and extenders such as starch,
CA 02214872 1998-09-04
X-10198
-17-
sugars, mannitol, and silicic derivatives; binding agents
such as carboxymethyl cellulose and other cellulose
derivatives, alginates, gelatin, and polyvinyl pyrrolidone;
moisturizing agents such as glycerol; disintegrating agents
S such as agar agar, calcium carbonate, and sodium
bicarbonate; agents for retarding dissolution such as
paraffin; resorption accelerators such as quaternary
ammonium compounds; surface active agents such as cetyl
alcohol, glycerol monostearate; adsorptive carriers such as
kaolin and bentonite; and lubricants such as talc, calcium
and magnesium stearate and solid polyethylene glycols.
Final pharmaceutical forms may be: pills, tablets, powders,
lozenges, syrups, aerosols, saches, cachets, elixirs,
suspensions, emulsions, ointments, suppositories, sterile
1S injectable solutions, or sterile packaged powders, and the
like, depending on the type of excipient used.
Additionally, the compounds of this invention are well
suited to formulation as sustained release dosage forms.
The formulations can also be so constituted that
they release the active ingredient only or preferably in a
particular part of the intestinal tract, possibly over a
period of time. Such formulations would involve coatings,
envelopes, or protective matrices which may be made from
polymeric substances or waxes.
The particular dosage of a compound of formula I
required to inhibit the symptoms and/or disease of a mammal,
including humans, suffering from the above maladies
according to this invention will depend upon the particular
disease, symptoms, and severity. Dosage, routes of
administration, and frequency of dosing is best decided by
the attending physician. Generally, accepted and effective
doses will be from l5mg to 1000mg, and more typically from
l5mg to 80mg, one to three times per day. Such dosages will
be administered to a patient in need thereof for at least
one month, or more typically for six months, or chronically.
The instant invention also provides methods for
inhibiting estrogen deficient pathologies including, for
CA 02214872 1998-09-04
X-10198
-18-
example, lack of birth control, postmenopausal syndrome
including, for example, osteoporosis, cardiovascular
disease, restenosis, and hyperlipidemia, certain cancers in
men such as prostate cancer, acne, hirsutism, dysfunctional
uterine bleeding, dysmenorrhea, and atrophic vaginitis
comprising administering to a mammal in need of treatment an
effective amount of a compound of formula I, and,
optionally, an effective amount of a progestin. One of
skill in the art will recognize that estrogenic agents have
a multitude of applications for treating estrogen deficient
pathologies well beyond those listed, infra. The instant
invention contemplates and encompasses such maladies
although not specified by name.
The formulations which follow are given for purposes of
illustration and are not intended to be limiting in any way.
The total active ingredients in such formulations comprises
from 0.1% to 99.90 by weight of the formulation. The term
"active ingredient" means a compound of formula I.
Formulation 1: Gelatin Capsules
Ingredient Quantity (mgjcapsule)
Active Ingredient 0.1-1000
Starch NF 0-500
Starch flowable powder 0-500
Silicone fluid 350 centistokes 0-15
The ingredients are blended, passed through a No. 45 mesh
U.S. sieve, and filled into hard gelatin capsules.
Formulation 2: Tablets
Ingredient Quantity (mg/tablet)
Active Ingredient 2.5-1000
Starch 10-50
Cellulose, microcrystalline 10-20
Polyvinylpyrrolidone 5
(as 10o solution in water)
Sodium carboxymethylcellulose 5
X-10198
CA 02214872 1997-09-08
-19-
Magnesium stearate 1
Talc 1-5
The active ingredient, starch, and cellulose are passed
through a No. 45 mesh U.S. sieve and mixed thoroughly. The
solution of polyvinylpyrrolidone is mixed with the resultant
powders which are then passed through a No. 14 mesh U.S.
sieve. The granules thus produced are dried at 50-60 oC and
passed through a No. 18 mesh U.S. sieve. The sodium
carboxymethylcellulose, magnesium stearate, and talc,
previously passed through a No. 60 mesh U.S. sieve, are
added to the above granules and thoroughly mixed. The
resultant material is compressed in a tablet forming machine
to yield the tablets.
Formulation 3: Aerosol
Ingredient Weight
Active Ingredient 0.25
Ethanol 29.75
Propellant 22 70.00
(Chlorodifluoromethane)
Total 100.00
The active ingredient is mixed with ethanol and the
mixture added to a portion of the propellant 22, cooled to -
oC and transferred to a filling device. The required
amount is then fed to a stainless steel container and
30 diluted with the remainder of the propellant. The valve
units are then. fitted to the container.
Formulation 4: Suppositories
Ingredient Weight
Active ingredient 150 mg
Saturated fatty acid
glycerides 3000mg
CA 02214872 1998-09-04
X-10198
-20-
The active ingredient is passed through a No. 60 mesh
U.S. sieve and suspended in the fatty acid glycerides which
had previously heated to their melting point. The mixture
is poured into a suppository mold and allowed to cool.
Formulation 5: Susper~sior_
Suspensions each containing 0.1-1000 mg of a compound
of formula I per 5 mL dose.
Ingredient Weight
Active Ingredient 0.1-1000 mg
Sodium carboxymethyl
cellulose 50 mg
Syrup 1.25 mL
Benzoic acid solution (0.1M) 0.10 mL
Flavor q.v.
Color q.v.
Purified water to total Total 5 mL
A compound of formula I is passed through a No. 45 mesh
U.S. sieve and mixed with the sodium carboxymethyl cellulose
and syrup to form a smooth paste. The benzoic acid
solution, flavor, and color diluted in water are added and the
mixture stirred thoroughly. Additional water is added to
bring the formulation to final volume.
The following Preparations and Examples are
provided to better elucidate the practice of the instant
invention and should not be interpreted in any way as to
limit the scope of same. Those skilled in the art will
recognize that various modifications may be made while not
departing from the spirit and scope of the invention. All
publications and patents mentioned in the specification
are indicative of the level of those skilled in the artLed
to which this invention pertains.
CA 02214872 1998-09-04
X-10198
-21-
NMR data for the following Examples were generated on a
GE 300 MHz NMR instrument, and anhydrous CDC13 was used as
the solvent unless otherwise indicated. Field strength for
13C ~ spectra was 75.5 MHz, unless otherwise indicated.
Preparation 1
2-(4-Methoxyphenyl)-3-bromo-6-methoxybenzo[b]thiophene
A slurry of 2-(4-methoxyphenyl)-6-
methoxybenzo[b]thiophene 1008 (370 mmol) in 1 L of CHC13
was heated to i~eflux then removed from the heat. A solution
of 19.3 mL (370 mmol) of bromine in 170 mL of carbon
tetrachloride was added dropwise as the solution slowly
cooled to room.temperature. The resulting mixture was
concentrated to dryness in vacuo to yield 129 g of the title
compound as a brown solid.
PMR: Consistent with the proposed structure
MS: 348 and 350 (M+) FD
EA: Calc: C, 55.03; H, 3.75 Found: C, 55.30; H, 3.70
C16H13BrO2S.
Preparation 2
3-Benzyloxy-bromobenzene
A slurry of 3-bromophenol 1008 (580 mmol),
benzylchloride 80g (700 mmol), and K2C03 1688 (1210 mmol) in
2 L of DMF was stirred for sixteen hour at ambient
temperature. The reaction mixture was filtered and
evaporated to dryness. The solid was pardoned between
CHC13 and water. The organic layer was separated, washed
twice with brine, and dried by filtration through anhydrous
Na2S04. The solution was evaporated to dryness. This
yielded 142.5 g of the title compound as a white solid.
PMR: Consistent with the proposed structure
MS: 262 and 264 (M+) FD
EA: Calc: C, 59.34; H, 4.21 Found: C, 59.59; H, 4.17
C13H11Br0
CA 02214872 1998-09-04
X-10198
-22-
Preparation 3
3-Benzyloxyphenyl boronic acid
A solution of 3-benzyloxy-bromobenzene 10 g (38 mmol)
in 150 mL of anhydrous THF was cooled to -70oC under a
nitrogen atmosphere. 28.5 mL of n-butyl lithium (1.6 M in
hexanes) was added dropwise to the solution. The reaction
mixture was stirred for 30 minutes, then tri-isopropyl
borate 10.6 mL (45.6 mmo1) was added. The reaction mixture
was allowed to warm to ambient temperature over a two hour
period. The reaction was quenched by the addition of 200 mL
of 1 N HC1 and the reaction mixture was stirred for an
additional hour. The slurry was extracted twice with EtOAc
and the organic layer separated and combined. The EtOAc
solution was washed twice with brine, dried with Na2S04, and
evaporated to a yellow oil. The product was crystallized
from ether-hexane. This yielded 4.85 g of r_he title
compound as a white solid.
PMR: Consistent with the proposed structure.
Preparation 4
2-(4-Methoxyphenyl)-3-(3-benzyloxyphenyl)-6-
methoxybenzo[b]thiophene
A solution of 2-(4-methoxyphenyl)-3-bromo-6-
methoxybenzo[b]thiophene 40 g (112 mmol) and 3-
benzyloxyphenyl boronic acid 51 g (224 mmol) in 1.4 L of
toluene and 1 L of EtOH was prepared. To this solution was
added a catalytic amount of
tetrakis(triphenylphosphine)palladium (0) and 180 mL of 2 N
aqueous Na2C03. The slurry was heated to reflux for one
hour and allowed to cool. The organic layer was separated
and washed twice with 0.1 N NaOH, twice with brine, dried
with Na2S04, and evaporated to dryness. The product was
chromatographed on a silica gel column eluted with a linear
gradient begining with EtOAc-Hexane (9:1) (v/v) and ending
with EtOAc-Hexane (4:1) (v/v). The desired fractions were
CA 02214872 1998-09-04
X-10198
-23-
determined by tic, combined, and evaporated to a clear oil.
This yielded 28 g of the title compound.
PMR: Consistent. with the proposed structure
MS: m/e=452 (M+) FD
EA: Calc: C, 76.96; H, 5.35 Found: C, 76.75; H, 5.44
C29H2403S
Preparation 5
2-(4-Methoxyphenyl)-3-(3-hydroxyphenyl)-6
methoxybenzo[b]thiophene
A slurry ivas prepared consisting of 2-(4-
methoxyphenyl)-3-(3-benzyloxyphenyl)-6-
methoxybenzo[b]thiophene in 1 L of EtOH, 250 mL of EtOAc,
and 40 mL of water. Palladium(0) black 4.04 g (38 mmol) and
ammonium formate 12.6 g (200 mmol) was added. The reaction
mixture was heated to reflux for one hour, then filtered hot
through "Celite"* and evaporated to dryness. The solid was
partioned between EtOAc and a saturated solution of NaHC03.
The organic layer was washed with brine, dried with Na2S04,
and evaporated to dryness. This yielded 12.8 g of the title
compound as a white solid.
PMR: Consistent with the proposed structure
MS: m/e=362 (M+) FD
EA: Calc: 72.90; H, 4.97 Found: C,73.11; H, 5.00
C22H1803S
Example 1
2-(4-Methoxyphenyl)-3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-6
methoxybenzo[b]thiophene hydrochloride
A slurry of 2-(4-Methoxyphenyl)-3-(3-hydroxyphenyl)-6-
methoxybenzo[b]thiophene 2.7 g (7.1 mmol), 2-chloroethyl-
piperidine hydrochloride 1.8 g (10.7 mmol), and K2C03 4.9 g
(35.5 mmol) in 200 mL of DMF was prepared. The reaction was
allowed to proceed for sixteen hours at ambient temperature.
The reaction mixture was evaporated to dryness and the solid
partitioned between EtOAc and water. The organic layer was
separated and washed with brine and dried with Na2S04. the
*Trademark
CA 02214872 1998-09-04
X-10198
-24-
solution was evaporated to a brown oil and re-dissolved in
80 mL of EtOAc. Dzy HC1 gas was bubbled into the EtOAc
solution and a precipitate formed. The solvent was removed
by evaporation. This yielded 2.8 g of the title compound as
a tan powder.
PMR: Consistent with the proposed structure
MS: m/e=473 (M-HCl) FD
EA: Calc: C, 68.28; H, 6.32; N, 2.75 Found: C, 68.57; H,
6.23; N, 2.45
C29H32C1N03S
Example 2
2- (4-Methoxyphenyl ) -3- [3- [3- (1-piperidinyl) propoxy] phenyl] -6
methoxybenzo[b]thiophene hydrochloride
A manner similar to that used in Example l, 3.09 g (8
mmol) of 2-(4-Methoxyphenyl)-3-(3-hydroxyphenyl)-6-
methoxybenzo[b)thiophene, 2.4 g (,12 mmol) of 1-(3-
chloropropyl)piperidine hydrochloride, 5.5q (40 mmol) of
K2C03 in 200 mL of DMF was converted to 2.8 g of the title
compound, isolated as a white solid.
PMR: Consistent with the proposed structure
MS: M/e= 488 (M+) FD
EA: Calc: C, 68.75; H, 6.54; N, 2.67 Found: C, 68.49; H,
6.64; N, 2.81
C3pH34C1N03S
Preparation 6
2-(4-Methoxyphenyl)-3-[3-(4-bromobutyl)phenyl]-6
methoxybenzo[b]thiophene
A slurry of 4.04 g (11 mmol) of 2-(4-Methoxyphenyl)-3-
(3-hydroxyphenyl)-6-methoxybenzo[b]thiophene, 1,4-
dibromobutane 26.3 mL (220 mmol), and 3.S g (25.3 mmol) of
K2C03 in 200 mL of 2-butanone was prepared. The reaction
mixture was heated to reflux for two hours, then filtered,
and evaporated to dryness. The resulting oil was
chromatographed on a silica gel column eluted with a linear
gradient begining with EtOAc-hexane (1:9) (v/v) and ending
CA 02214872 1998-09-04
X-10198
-25-
with EtOAc-hexane (1:4) (v/v). The desired fractions were
combined and evaporated to a yellow oil. This yielded 5 g
of the title compound.
PMR: Consistent with the proposed structure
MS: m/e=497 and 499 (M+) FD
EA: Calc: C, 62.78; H, 5.07 Found: C, 62.59; H, 5.28
C26H25BrN03S
Example 3
2-(4-Methoxyphenyl)-3-[3-[4-(1-piperidinyl)butoxy]phenyl]-6-
methoxybenzo[b]thiophene hydrochloride
2-(4-Methoxyphenyl)-3-[3-(4--bromobutyl)phenyl]-6-
methoxybenzo[b]thiophene 5.4 g (11 mmol), 4.4 mL (44 mmol)
of piperidine, and 6 g (44 mmol) of K2C03 were added to 100
1S mL of DMF. The reaction mixture was heated to reflux for
one hour, filtered, and evaporated to dryness. The
resulting solid was pardoned between EtOAc and water and
the organic layer separated. The EtOAc solution was washed
thrice with water, twice with brine, and dried with Na2S04.
The resulting solution was evaporated to a brown oil and re-
dissolved in 80 mL of EtOAC. Dry HC1 gas was bubbled through
the EtOAc solution and a white precipitate formed. The
solvent was removed by evaporation. This yielded 2.7 g of
the title compound as a tan powder.
PMR: Consistent with the proposed structure
IR: (KBr) 3691, 3425, 2960, 2839, 2453, 2374,1603, 1577,
1542,1508, 1473, 1439, 1352,1292, 1249, 1179, 1146, 1061,
1034, 832 cm-1
HDMS: Calcd for C31H36N03S (M-C1): 502.2416 Fd: 502.2426
Example 4
2-(4-Hydroxyphenyl)-3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-6
hydroxybenzo[b]thiophene hydrochloride
2-(4-Methoxyphenyl)-3-[3-[2-(1-
piperidinyl) ethoxy] phenyl] -6-methoxybenzo [b] thiophene
hydrochloride, 2 g (4 mmol) was dissolved in 125 mL of
CA 02214872 1998-09-04
X-10198 ..
-26-
CH2C12 and cooled to 0°C. 1.0 mL (10 mmol) of BBr3 was
added and the reaction mixture was stirred at OoC for 3
hours under a nitrogen atmosphere. The reaction was
quenched by pouring into a mixture of 125 mL of aqueous
NaHC03, 25 mL of iso-propanol, and 250 mL of CHC13. The
organic layer was separated and washed twice with brine,
dried with Na2S04, and evaporated to dryness. The resulting
solid was re-dissolved in 150 mL of EtOAc and dry HC1 gas
was bubbled through. The solvents were removed by
evaporation. This yielded 850 mg of the title compound as a
white powder. '~
PMR: Consistent with the proposed structure
IR: (KBr) 3217, 2950, 2739, 1590, 1586, 1508, 1466, 1433,
1360,1262, 1216, 1171, 1148, 907 cm-1
HRMS: Calcd. for C27H28N03S: 446.1790 Fd: 446.1795
Example 5
2-(4-Hydroxyphenyl)-3-[3-(1-piperidinyl)propoxy]phenyl]-6
hydroxybenzo[b]thiophene
1.1g (2.1 mmol) of 2-(4-methoxyphenyl)-3-[3-[3-(1-
piperidinyl)propoxy]phenyl]-6-methoxybenzo[b]thiophene
hydrochloride was dissolved in 60 mL of CH2C12 and cooled to
0°C. 0.5 mL (5.25 mmol) of BBr3 was added and the reaction
mixture was stirred for ninety minutes at 0°C under a nitrogen
atmosphere. The reaction was quenched by pouring it into a
mixture of 125 mL of NaHC03, 25 mL of isopropanol, and 250
mL of CHC13. The organic layer was separated and washed
twice with brine, dried with Na2S04, and evaporated to
dryness. The crude product was chromatographed on a silica
gel column eluted with a linear gradient begining with CHC13
and ending with CHC13-MeOH (9:1) (v/v). The desired
fractions were combined and evaporated to dryness. The
hydrochloride salt was prepared as in Example 4. This
X-10198
CA 02214872 1997-09-08
-27-
yielded 550 mg of the title compound as a tan amorphous
solid.
PMR: Consistent with the proposed structure.
MS: m/e=460 (M-C1)
HRMS: Calcd. for C28H3pN03S =460.1950 Fd: 460.1946
Example 6
2-(4-Hydroxyphenyl)-3-[3-(1-piperidinyl)butoxy]phenyl]-6
hydroxybenzo[b]thiophene hydrochloride
In a manner similar to that of Example 4, 1.1 g (2.04
mmol) of 2-(4-methoxyphenyl)-3-[3-[4-(1-
piperidinyl)butoxy]phenyl]-6-methoxybenzo[b]thiophene
hydrochloride with 0.5 mL (5.1 mmol) of BBr3 was converted
to 370 mg of the title compound as a tan amorphous powder.
PMR: Consistent with the proposed structure
MS: m/e=473 (M+) FD
HRMS: Calcd. for C2gH32N03S =474.2103 Fd: 474.2097
In the examples illustrating the methods, a
postmenopausal model was used in which effects of different
treatments upon circulating lipids were determined.
Seventy-five day old female Sprague Dawley rats (weight
range of 200 to 225g) were obtained from Charles River
Laboratories (Portage, MI). The animals were either
bilaterally ovariectomized (OVX) or exposed to a Sham
surgical procedure at Charles River Laboratories, and then
shipped after one week. Upon arrival, they were housed in
metal hanging cages in groups of 3 or 4 per cage and had ad
libitum access to food (calcium content approximately 0.5%)
and water for one week. Room temperature was maintained at
22.2° ~ 1.7° C with a minimum relative humidity of 40%. The
photoperiod in the room was 12 hours light and 12 hours
dark.
Dosing Regimen Tissue Collection. After a one week
acclimation period (therefore, two weeks post-OVX) daily
CA 02214872 1998-09-04
x-1019s
-28-
dosing with test. compound was initiated. 1?a-ethynyl
estradiol or the test compound were given orally, unless
otherwise stated, as a suspension in 10
carboxymethylcellulose or dissolved in 20° cyclodextrin.
Animals were dosed daily for 4 days. Following the dosing
regimen, animals were weighed and anesthetized with a
ketamine:xylazine (2:1, V:V) mixture and a blood sample was
collected by cardiac puncture. The animals were then
sacrificed by asphyxiation with C02, the uterus was removed
through a midline incision, and a wet uterine weight was
determined.
Cholesterol Analysis. Blood samples were allowed to clot at
room temperature for 2 hours, and serum was obtained
following centrifugation for 10 minutes at 3000 rpm. Serum
cholesterol was determined using a Boehringer Mannheim
Diagnostics high performance cholesterol assay. Briefly the
cholesterol was oxidized to cholest-4-en-3-one and hydrogen
peroxide. The hydrogen peroxide was then reacted with
phenol and 4-aminophenazone in the presence of peroxidase to
produce a p-quinone imine dye, which was read
spectrophotometrically at 500 nm. Cholesterol concentration
was then calculated against a standard curve.
Uterine Eosinophil Peroxidase (EPO) Assay. Uteri were kept
at 4° C until time of enzymatic analysis. The uteri were
then homogenized in 50 volumes of 50 mM Tris buffer (pH -
8.0) containing 0.0050 "Triton X-100"*. Upon addition of 0.01%
hydrogen peroxide and 10 mM O-phenylenediamine (final
concentrations) in Tris buffer, increase in absorbance was
monitored for one minute at 450 nm. The presence of
eosonophils in the uterus is an indication of estrogenic
activity of a compound. The maximal velocity of a 15 second
interval was determined over the initial, linear portion of
the reaction curve.
*Trademark
X-10198
CA 02214872 1997-09-08
-29-
Source of Compound: 17a-ethynyl estradiol was obtained
from Sigma Chemical Co., St. Louis, MO.
Influence of Formula I Compounds on Serum Cholesterol and
Determination of Agonist/Non-Agonist Activity
Data presented in Table 1 below show comparative
results among ovariectomized rats, rats treated with 17a-
ethynyl estradiol (EE2; an orally available form of
estrogen), and rats treated with certain compounds of the
instant invention. Although EE2 caused a decrease in serum
cholesterol when orally administered at 0.1 mg/kg/day, it
also exerted a stimulatory action on the uterus so that EE2
uterine weight was substantially greater than the uterine
weight of ovariectomized test animals. This uterine
response to estrogen is well recognized in the art.
Not only did the compounds of the instant invention
generally reduce serum cholesterol compared to the
ovariectomized control animals, but uterine weight was only
minimally increased to slightly decreased with the majority
of the formula compounds tested. Compared to estrogenic
compounds known in the art, the benefit of serum cholesterol
reduction without adversely affecting uterine weight is
quite rare and desirable.
As is expressed in the data below, estrogenicity also
was assessed by evaluating the adverse response of
eosinophil infiltration into the uterus. The compounds of
the instant invention did not cause any increase in the
number of eosinophils observed in the stromal layer of
ovariectomized rats, while estradiol cause a substantial,
expected increase in eosinophil infiltration.
The data presented in Table 1 below reflects the
response of 5 to 6 rats per treatment.
CA 02214872 1997-09-08
X-10198
-30
Table 1
Compound No. Dose Uterine Uterine Serum
mg/kga Weight Eosinophil Cholest.
% Incb (Vmax) c % Decd
EE2e 0.1 118.6* 234.2* 89.3*
Ex 1 0.1 24 7.5 25.8
1.0 37.2* 22.2 56.1* 10.0
68.2* 103.5* 71.1*
Ex 2 0.1 20.2 24.0 59.1*
1.0 35.7* 32.4 76.5*
.
10.0 39.1* 32.1 69.4*
Ex 3 0.1 23.9 4.8 35.5*
1.0 62.1* 43.5* 64.4*
10.0 65.0* 91.2* 78.0*
Ex 4 0.1 9.1 4.8 33.3*
1.0 5.6 4.8 57.2*
10.0 78.7* 103.8* 81.0*
Compound Af 0.1 24.6* 21.0* 45.4*
1.0 64.8* 49.9* 68.8*
10.0 41.7* 55.9* 65.3*
a mg/kg PO
b Uterine Weight % increase he ovariectomized
versus t
controls
c Eosinophil peroxidase Vmax
d Serum cholesterol decrease ovariectomized controls
versus
17-a-Ethynyl-estradiol
f 2-(4-Hydroxyphenyl)-3- [4-[2-(1-piperidinyl)ethoxy]phenyl]-
6-hydroxybenzo[b]thiophene : Crenshaw U.S.Pat.
(see
No. 3,413,305)
* p<.05
In addition to the demonstratedbenefits of
the
compounds of the instant invention, the above data clearly
demonstrate that compoun ds of Formula I are not rogen
est
mimetics. Furthermore, no deleterious toxicological effects
(for example, survival umbers) wereobserved with any
n
treatment.
X-10198
CA 02214872 1997-09-08
-31-
Osteoporosis Test Procedure
Following the General Preparation Procedure, infra,
the rats are treated daily for 35 days (6 rats per treatment
group) and sacrificed by carbon dioxide asphyxiation on the
36th day. The 35 day time period is sufficient to allow
maximal reduction in bone density, measured as described
herein. At the time of sacrifice, the uteri are removed,
dissected free of extraneous tissue, and the fluid contents
are expelled before determination of wet weight in order to
confirm estrogen deficiency associated with complete
ovariectomy. Uterine weight is routinely reduced about 75%
in response to ovariectomy. The uteri are then placed in
10% neutral buffered formalin to allow for subsequent
histological analysis.
The right~femurs are excised and digitilized x-rays
generated and analyzed by an image analysis program (NIH
image) at the distal metaphysis. The proximal aspect of the
tibiae from these animals are also scanned by quantitative
computed tomography.
In accordance with the above procedures, compounds of
the instant invention and ethynyl estradiol (EE2) in 200
hydroxypropyl (3-cyclodextrin are orally administered to test
animals. Distal femur metaphysic and proximal tibiae data
are compared to intact and ovariectomized test animals.
Results are reported as percent protection relative to
ovariectomy.
Ovariectomy of the test animals causes a significant
reduction in femur density compared to intact, vehicle
treated controls. Orally administered ethynyl estradiol
(EE2) prevents this loss, but the risk of uterine
stimulation with this treatment is ever-present.
Estrogen Dependent Breast Cancer:
MCF-7 Proliferation Assay Test Procedure
MCF-7 breast adenocarcinoma cells (ATCC HTB 22) are
maintained in MEM (minimal essential medium, phenol-red
CA 02214872 1998-09-04
X-10198
-32-
free, Sigma St. Louis MO) supplemented with lOp fetal bovine
serum (FBS) (v/v), L-glutamine (2mM), sodium pyruvate (1mM),
HEPES (lOmM), non-essential amino acids and bovine insulin
(1ug/mL). Ten days prior to the assay, the MCF-7 cells are
switched to maintenance medium supplemented with 10%
dextran-coated charcoal stripped fetal bovine serum (DCC-FBS)
assay medium in place of the 10s FBS to deplete internal
stores of estrogen. MCF-7 cells are removed from the
maintenance flasks using a cell dissociating medium (Ca/Mg
free HBSS (phenol-red free) supplemented with 10 mM HEPES
and 2 mM EDTA.Y"Cells are washed twice with the assay medium
and adjusted to 80,000 cells/mL. Approximately 100~L (8,000
cells) are added to a flat-bottomed microculture well
(Costar 3596) and incubated at 37o C in a 5o C02 humidified
incubator for 48 hours to allow cell adherence and
equilibrium after transfer. Serial dilutions of the
compounds of formula I or DMSO as a diluent control are
prepared in assay medium and
50 ~.L transferred to triplicate microcultures followed by 50
~,L of assay medium for a final volume of 200 ~L. After an
additional 48 hours of incubation, the microcultures are
pulsed with tritiated thymidine (1 ~Ci/well) for 4 hours.
The cultures are terminated by freezing at -70°C for 24 hours
followed by thawing and harvesting of microcultures using a
Skatron Semiautomatic Cell Harvester. Samples are counted
by liquid scintillation. Fifty percent inhibitory
concentration of the test drugs (IC50) are determined versus
the control (DMSO). Compounds of the present invention are
active in this experimental model as seen below in Table 2.
Table 2
Compound IC50
4 8 nM
S 0.2 nM
3 5 6 2 nM
X-10198
CA 02214872 1997-09-08
-33-
DMBA-Induced Mammary Tumor Inhibition
Estrogen-dependent mammary tumors are produced in female
Sprague-Dawley~rats which are purchased from Harlan
Industries, Indianapolis, Indiana. At about 55 days of age,
the rats receive a single oral feeding of 20 mg of 7,12-
dimethylbenzo[a]anthracene (DMBA). About 6 weeks after DMBA
administration, the mammary glands are palpated at weekly
intervals for the appearance of tumors. Whenever one or
more tumors appear, the longest and shortest diameters of
each tumor are measured with a metric caliper, the
measurements are recorded, and that animal is selected for
experimentation. An attempt is made to uniformly distribute
the various sizes of tumors in the treated and control
groups such that average-sized tumors are equivalently
distributed between test groups. Control groups and test
groups for each experiment contain 5 to 9 animals.
Compounds of Formula I are administered either through
intraperitoneal injections in 2o acacia, or orally. Orally
administered compounds are either dissolved or suspended in
0.2 mL corn oil. Each treatment, including acacia and corn
oil control treatments, is administered once daily to each
test animal. Following the initial tumor measurement and
selection of test animals, tumors are measured each week by
the above-mentioned method. The treatment and measurements
of animals continue for 3 to 5 weeks at which time the final
areas of the tumors are determined. For each compound and
control treatment, the change in the mean tumor area is
determined.
